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Objective. Benign thyroid nodules are a common occurrence whose only remedy, in case of symptoms, has always been surgery
until the advent of new techniques, such as radiofrequency ablation (RFA).This study aimed at evaluating RFA efficacy, tolerability,
and costs and comparing them to hemithyroidectomy for the treatment of benign thyroid nodules.Design andMethods. 37 patients
who underwent RFAwere retrospectively compared to 74 patients surgically treated, either in a standard inpatient or in a short-stay
surgical regimen. Efficacy, tolerability, and costs were compared. The contribution of final pathology was also taken into account.
Results. RFA reduced nodular volume by 70% after 12 months and it was an effective method for treating nodule-related clinical
problems, but it was not as effective as surgery for the treatment of hot nodules. RFA and surgery were both safe, although RFA had
less complications and pain was rare. RFA costed C1,661.50, surgery costed C4,556.30, and short-stay surgery costed C4,139.40 per
patient. RFA, however, did not allow for any pathologic analysis of the nodules, which, in 6 patients who had undergone surgery
(8%), revealed that the nodules harboured malignant cells. Conclusions. RFA might transform our approach to benign thyroid
nodules.
1. Introduction
Thyroid nodules are an extremely common occurrence and
their prevalence in the general population is estimated to
range between 50% and 67%, according to autoptic [1] and
ultrasonographic [2] data. Until recently, though, only a few
remedies have been available for such a common disease.
According to current guidelines [3], benign thyroid nodules
should be followed up clinically. In order to avoid nodule
enlargement, levothyroxine therapy, whose efficacy is still
limited [4], and/or iodine should be taken into account in
young patients with small nodules living in iodine-deficient
areas. However, if nodular growth causes the onset of symp-
toms or cosmetic concerns the only available remedy so far
has been surgery. Not only is curative surgery invasive but
it also has several drawbacks [5]. Therefore, new treatment
modalities for such a common disease are needed.
Radiofrequency ablation (RFA) is a relatively new tech-
nique that seems a safe and effective method for the debulk-
ing of large benign thyroid nodules [6] and a promising
treatment modality for autonomously functioning nodules
[7–11]. Nevertheless, guidelines are cautious and RFA is not
recommended yet in the routine management of benign
thyroid nodules [3, 4].
Here we aimed at (i) evaluating RFA efficacy, tolerability,
and costs and (ii) comparing RFA outcomes to those of
hemithyroidectomy, including short-stay thyroid surgery, for
the treatment of benign thyroid nodules.
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2. Materials and Methods
2.1. Patient Selection and Study Design
2.1.1. Patient Selection. To assess RFA efficacy, complications,
and costs we followed 37 patients who underwent RFA of
their thyroid nodules between March 2012 and May 2013.
Overall, 38 RFA have been performed in 37 patients, as in
one case the treatment was repeated. Before the procedure,
nodules were evaluated by fine needle aspiration biopsy
(FNAB) twice and classified according to the British and
Italian reporting systems for thyroid cytopathology [12].
RFA was performed on benign solitary nodules (diagnostic
categoryThy2/Tir2) that measured >2 cm and caused clinical
problems (neck pain, voice change, foreign body sensation,
discomfort and cough, and cosmetic concerns) or problems
related to thyrotoxicosis, according to current recommen-
dations [6]. Since caution should be exercised in patients
with contralateral vocal cord palsy [6], patients presenting
with voice changes underwent an otolaryngological visit and
laryngoscopy to exclude such injury.
To compare RFA outcomes with surgery, we selected
74 patients among 525 patients who underwent thyroid
surgery from May 2005 to May 2013. These were all patients
with benign single thyroid non-autoimmune nodules, who
had undergone hemithyroidectomy, performed either in a
standard inpatient surgical regimen (>24 hours, 𝑛 = 64,
hEMItx) or in a short-stay regimen (<24 hours, 𝑛 = 10, short-
stay). Patients who had already undergone contralateral
thyroid lobectomy or who had had cytological preoperative
diagnosis of malignancy (diagnostic category Thy5/Tir5) or
suspected malignancy (Thy4/Tir4) as well as patients with
nodules of undetermined significance (Thy3/Tir3) and/or
with increased calcitonin levels were excluded from the study.
This work was approved by the Ethical Committee of the
Azienda Ospedaliero Universitaria di Trieste and informed
consent was obtained from each patient, after full explanation
of the purpose and nature of all procedures used, before
inclusion in the study.
2.1.2. Study Design. This study aimed at evaluating RFA
outcomes and at comparing them to those of surgery. Firstly,
to assess RFA efficacy and tolerability, patients underwent a
medical visit, ultrasonography (US), and thyroid-stimulating
hormone (TSH) measurement at baseline, 1, 3, 6, and 12
months after the procedure. During these visits, medication,
nodule-related symptoms (yes/no), cosmetic score (1 = no
palpable mass; 2 = palpable mass; 3 = mass visible on
swallowing; 4 = easily visible mass), cosmetic results (poor,
acceptable, good, and excellent), pain, and/or other com-
plications (hematomas, skin burns, fever, and voice change)
were recorded. To measure nodule volume (V) and volume
reduction (Vreduction) the following formulas were used:
𝑉 = 𝜋𝑎𝑏𝑐/6 (where 𝑉 is the volume, a is the maximum
diameter, and b and 𝑐 are the other two perpendicular diam-
eters) and (Vreduction = (initial − finalV/initialV)∗100).
Therapeutic success was defined as a volume reduction >50%
[6]. Vascularity was evaluated according to a 4-point scale
where 0 is defined as no visible flow, 1 as peripheral flow only,
2 as peripheral flow with a small amount of central flow, 3
as peripheral flow plus extensive intranodular flow, and 4 as
central flow only.
Then, to compare the efficacy and tolerability of RFA
to surgery, we took patient history, any current complaints
(neck symptoms yes/no), cosmetic results (graded as poor,
acceptable, good, and excellent), drug history, and TSH at
baseline and one year after surgery. Pain and complications
of surgery were analysed retrospectively from the medical
records.
The endpoints for efficacy were (i) cure of nodule-related
symptoms, (ii) patient satisfaction with cosmetic results, and
(iii) antithyroid drugs (ATD) withdrawal. Tolerability was
expressed as (i) cases of postoperative pain, (ii) cases of
iatrogenic hypothyroidism, and (iii) number of complica-
tions. Cost analysis is discussed below. The contribution of
final pathology to patient management was also analysed and
discussed.
2.2. Radiofrequency Ablation. RFA was performed in an
outpatient regimen by a well-trained radiologist experienced
in US, FNAB, and RFA procedures. Before ablation, an intra-
venous access was obtained via an antecubital vein. Patients
were placed in a supine position with their neck extended.
RFA did not require general anesthesia, and our patients
underwent only local anesthesia at the puncture site with 2%
lidocaine hydrochloride.We used a radiofrequency generator
(VIVA RF generator; AMICA RF generator) and 18-gauge
internally cooled electrodes with a 0.7–1.0–1.5 cm active-tip
(star RF probes STARmed; Amica probes, HS AMICA).
The electrode was inserted into the thyroid nodule with a
transisthmic approach [13] under US-guidance by using a 7–
16MHz linear probe on a real-time US system (Aplio XG,
Toshiba Medical Systems Corp.), as shown in Figure 1(a).
To perform RFA the moving-shot technique was used [13].
Ablation was begun with 30W, starting from the deepest
areas of the nodule. If a hyperechoic zone had not formed
at the electrode tip within 5–10 seconds, radiofrequency
power was progressively increased in 10W steps up to 60W.
The power would have been reduced or turned off in cases
where patients could not tolerate pain during ablation, but
no such case was encountered in our cohort. Moreover,
during the procedure there was an anaesthetist to assist the
radiologist in case of pain [6], vasovagal reactions [6], or
interference with pacemaker devices [14], but no such case
was encountered in our cohort. Ablation was terminated
when transient hyperechoic zones could be identified around
the whole nodule, as shown in Figures 1(b)-1(c). At the end
of the procedure a mild compression was applied to the
site of the needle insertion for 5–10 minutes and patients
remained under observation for a few hours in case they had
complications. Pain was recorded 4 hours after the procedure
and scored according to the visual analogue scale (VAS)
ranging from 0 to 10 with the words “no pain = 0” on the left
hand side and “worst possible pain = 10” on the right hand
side.
2.3. Hemithyroidectomy: Surgical Technique. Patients were
allocated to short-stay hemithyroidectomy according to their
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Figure 1: (a) Transverse US image shows the transisthmic approach.The probe, whose active part is placed in the nodule through its isthmus,
is inserted from the medial to the lateral part of the nodule and is visible along its longitudinal axis. (b-c) Transverse US images show the
moving-shot technique. RFA is performed unit by unit, aiming at ablating all the subunits of the nodule, which turn into microbubbles
(hyperechoic areas with posterior barrage of the ultrasound beam). Initially, (a) the probe tip is positioned in the medial and deepest part of
the nodule and subsequently (b-c) in its most superficial and lateral parts.
age, residence, nodule size, and comorbidities [15]. All opera-
tions were carried out by the same team, which included two
surgeons (lead and assistant surgeon). Hemithyroidectomy
was performed by a single access of 2–5 cm in the middle
area of the neck, approximately 2 cm above the sternal notch.
Patients, under general anaesthesia, were placed in the supine
position with the neck extended. Minimal subplatysmal flaps
were created. The midline was incised and the strap muscles
were retracted laterally. The vessels of the upper thyroid
peduncle were selectively ligated or closed by conventional
vascular clips. Special care was taken to preserve the parathy-
roid glands and the inferior laryngeal nerve. Once the thyroid
lobe and isthmus had been removed, the area was examined
for bleeding. If there was no bleeding, the incision was
closed with sutures. In some cases, a surgical drain was
placed to remove fluids from the area in the following days.
Anaesthesia was discontinued and medication was given to
wake the patient. In those patients who underwent standard
inpatient hemithyroidectomy, postoperative pain and serum
calciumweremeasured 4 and 24 hours after surgery, together
with parathormone (PTH).Those who underwent short-stay
surgery were admitted the day of operation and observed
overnight. Here postoperative pain and serum calcium were
evaluated 4 and 20 hours after surgery, together with PTH.
All the patients underwent laryngoscopy after the procedure.
Discharge criteria included no wound or airway problems,
stable vital signs, tolerance of normal diet and activity, and
an upsloping serum calcium curve.
2.4. Cost Analysis. Cost analysis included the procedure
(RFA or surgery) and the respective pre- and postprocedural
exams.
2.4.1. RFA Costs. Preprocedural exams included laboratory
tests (full blood count, coagulation tests, TSH, thyroid
hormones, calcitonin, and thyroid autoantibodies), US and
anaesthesiological visit, and an otolaryngological visit in
selected cases (among our patients, 2 out of 37 underwent
such a visit). The cost of the procedure included the equip-
ment, consisting of scanner, needle, and drugs, as well as the
personnel, consisting of one radiologist, one anaesthetist, and
two nurses. In particular, the cost of any US scanner can
be divided into depreciation and maintenance. Apart from
maintenance, which is negligible, the purchase cost of our US
scanner was C97,489, which equals an average annual cost
of C12,186 over 8 years of depreciation. Therefore, assuming
250 working days per year, the daily cost of the scanner is
C48.74 per day and since it is used for 12 hours per day and
the length of one RFA is 45minutes, the final cost of a scanner
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is C3.04 per exam. Drugs were lidocaine (C0.013/mL),
midazolam (C0.099/mL), fentanyl (C0.140/mL), droperidol
(C3.168/mL), and saline (C0.834/mL).The cost of the radiol-
ogist and the anaesthetist was calculated according to their
working time, which is 1,330 hours/year, and their gross
annual salary, which is C101,040 in both cases (excluding
social security and termination bonus), corresponding to a
salary of C76 per hour. Likewise, the gross annual salary of
a nurse is C39,174 (excluding social security and termination
bonus), corresponding to a salary of C29 per hour. Postpro-
cedural exams included TSH measurement and a US scan.
2.4.2. Surgical Costs. Preprocedural exams included labora-
tory tests (including full blood count, urea and electrolytes,
glucose, urine analysis, liver function test, coagulation blood
tests, blood type, HIV and markers of hepatitis, and TSH),
ECG, chest X-ray, and otolaryngological and anaesthesiolog-
ical visits. The costs of the procedure included hospital stay
(C375/night), the operating theatre (C24/min), the variable
costs for technical textiles (C31.50), the sterilization of sur-
gical instruments (C95.30), scalpels (C0.20), suction can-
nulas (C23.80), sutures (C23.99), bipolar forceps (C19.05),
tampons (C0.69), and Redon sets (C3.04). The drugs that
were used were remifentanil (C304.20/5mg) and desflurane
(C0.35/mL). Personnel consisted of two surgeons, one theatre
nurse, two nurses, and one anaesthetist, whose costs were
calculated as above. Postprocedural exams were laboratory
tests (calcium, PTH) and an otolaryngological visit.
2.5. Statistical Analysis. Continuous variables were evaluated
by ANOVA. 𝜒2 test was used to compare sex, nodules’
characteristics, symptoms, hyperthyroidism, and autoimmu-
nity between the two groups. The criterion for statistical
significance was 𝑃 < 0.05. All analyses were conducted using
SAS (SAS Institute Inc., Cary, NC, USA).
3. Results
The characteristics of the thyroid nodules are reported in
Table 1. There were no differences between the nodules
treated by RFA and those treated by surgery in terms of cystic
component, macrocalcifications, and vascularization. In this
study, RFA significantly reduced thyroid nodule volumes
as shown in Figure 2. In particular, the nodules’ volume
was 12.45 ± 2.52mL at baseline, 6.44mL ± 1.77mL after
1 month from the procedure (𝑃 < 0.05 versus baseline),
5.45 ± 1.50mL after 3 months (𝑃 < 0.05 versus baseline),
4.56 ± 1.40mL after 6 months (𝑃 < 0.05 versus baseline),
and 3.91 ± 0.98mL after 12 months (𝑃 < 0.05 versus
baseline). In other words, the volume decreased by 47%,
61%, 66%, and 70% at 1, 3, 6, and 12 months after RFA.
The greatest volume reduction was observed within the first
month and this was more pronounced in the lesions with
more than 50% of liquid content. Therapeutic success was
achieved with a single session in 36 out of 37 patients, as
only one patient required two sessions to achieve a final
volume reduction of 77%. This patient had a solid nodule,
with peripheral plus intranodular flow, measuring 42 × 36
Table 1: Patients’ characteristics at baseline before either RFA or
surgery.
Characteristics RFA(𝑛 = 37)
Surgery
(𝑛 = 74) 𝑃 value
Age (years) 58.3 ± 3.6 54.9 ± 3.4 n.s.
Sex (M/F) 12/25 17/57 n.s.
Nodule maximum Ø (mm) 35.7 ± 2.5 38.8 ± 3.2 n.s.
Nodule volume (mL) 12.4 ± 2.5 12.8 ± 2.1 n.s.
Solid nodules (Y/N) 28/9 43/31 n.s.
Vascularity 2.1 ± 0.1 2.1 ± 0.2 n.s.
Macrocalcifications (Y/N) 8/29 19/55 n.s.
Patients with symptoms
(Y/N) 13/24 43/31
∗ 0.03
Hyperthyroidism (Y/N) 12/25 20/54 n.s.
TSH (microU/mL) 1.2 ± 0.2 1.3 ± 1.9 n.s.
Calcitonin (pg/mL) 1.8 ± 0.3 2.8 ± 0.5 n.s.
Anti-TPO and/or anti-TG
Ab (Y/N) 3/34 7/67 n.s.
Results are expressed as mean ± SEM. Anti-TPO Ab, anti-thyroperoxidase
antibodies; anti-TG Ab, anti-thyroglobulin antibodies; n.s., nonsignificant;
RFA, radiofrequency ablation; TSH, thyroid-stimulating hormone; Y/N,
yes/no. Solid nodules had less than 50% of cystic component.
× 31mm. In this case, RFA was repeated 6 months after
the first session because the nodule had decreased less than
50% of its initial volume. Apart from volume reduction,
RFA lessened nodular echogenicity and made intranodular
vascularity disappear, as shown in Figure 3. On the other
hand, hemithyroidectomy was successfully completed in all
the cases. In particular, among the 74 patients who under-
went surgery, 64 subjects underwent a hemithyroidectomy
performed in a standard inpatient surgical regimen and 10
subjects underwent a hemithyroidectomy performed in a
short-stay surgical regimen.
Patients’ characteristics at baseline are reported in Table 1.
The groups differed only in terms of number of patients with
neck symptoms, which was higher in the surgical group.
Focusing on the efficacy of these techniques, RFA was able
to cure nodule-related symptoms in the majority of patients
(11 patients out of 13) and was not inferior to surgery, as
shown in Table 2. In particular, while neck symptoms were
resolved completely in 11 patients out of 13 treated by RFA,
they ameliorated in the other 2 cases, as these patients were
suffering from gastroesophageal reflux disease, which might
have contributed to their local discomfort. Secondly, there
were no differences between RFA and surgery in terms of
cosmetic results, which were excellent for the vast majority
of patients in both groups (35 out of 37 patients for RFA
and 65 out of 74 for surgery). In particular, RFA significantly
reduced the cosmetic score, which went down from 3.4 to 2.4
per patient (𝑃 < 0.05); in other words, nodules that were
visible could no longer be seen after the procedure. Cosmetic
results were graded as “excellent” by 35 patients (94%), while
the remaining two had nodules measuring more than 35mL
initially which resulted in a final volume of 15mL. In these
two cases, cosmetic results were scored as “acceptable.” On
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Figure 2: Longitudinal B-mode and power Doppler US images, obtained before (a-b) and after RFA (c-d), show the effects of the procedure
at 1 month. The danger triangle, which remains undertreated, is clearly visible on the medial side of the nodule (c-d). Apart from the overall
reduction in size, the treated area of the nodule appears hypoechoic and avascular (c-d).
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Figure 3: Volume (mL) reduction at 1, 3, 6, and 12months after RFA.
Data are expressed as mean ± SEM. ∗𝑃 < 0.05 versus baseline.
the other hand, 88% of the patients (65) who had undergone
surgery judged the results as “excellent,” while they were
“good” for 9% of the patients (7) and “acceptable” only for
3% of the patients (2), depending on their scar. In particular,
in our cohort, the cosmetic benefit of thyroid nodule removal
was felt to outweigh the presence of a scar in 65 patients out
of 74, while in the remaining 9 patients the scar compromised
the final cosmetic result [16].
Overall, the volume reduction achieved by RFA did not
affect thyroid function, which remained unchanged through-
out the entire follow-up period. In particular, TSHwas 1.30±
0.25 𝜇U/mL at baseline, 1.48±0.25 𝜇U/mL at 1 month, 1.24±
0.22 𝜇U/mL at 3 months, 0.95 ± 0.15 𝜇U/mL at 6 months,
and 1.37 ± 0.28 𝜇U/mL at 12 months after the procedure.
Having said that, in the subgroup of hyperthyroid patients
(𝑛 = 12), RFA improved thyroid function as TSH increased
from 0.28 ± 0.08 microU/mL to 1.35 ± 0.31 microU/mL
(𝑃 < 0.05) after just one month from the procedure and
it was maintained throughout the study period. Thanks to
this effect, 4 patients out of 12 could stop or avoid taking
any ATD, as their thyroid function normalized completely,
whereas the remaining 8 patients could reduce the number
of tablets from 1 tablet every day to 1 tablet every two days.
Nevertheless, this effect was not enough for these 8 patients
and RFA was significantly less effective compared to surgery
for the treatment of autonomously functioning nodules, as
shown in Table 2.
RFA was extremely well tolerated. Postoperative pain was
rare as in only 2 cases out of 38 sessions pain was reported.
Pain was mild, was treated by paracetamol, scored 2.5 ±
0.8 points, and ceased within 2 weeks. Apart from this, in
our study, RFA complications were 1 case of transient voice
change and 1 case of late-onset, painless thyroiditis with
transient thyrotoxicosis. The voice change was treated by
prednisone and was resolved within 1 and a half months. The
late-onset painless thyroiditis with thyrotoxicosis developed
3 months after the procedure and resolved spontaneously
within 30 days. Moreover, such thyroiditis did not cause
hypothyroidism. There were no vasovagal reactions or cases
of haemorrhage, skin burn, or fever. Surgery was also well
tolerated, but not as much as RFA (see Table 2). Pain was
always treated by paracetamol postoperatively so it was mild
and scored on average 2.9 ± 0.1. Surgical complications
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Table 2: Efficacy and tolerability of RFA compared to surgery.
Outcomes RFA(=37)
Surgery
(=74)
Efficacy
Patients with symptoms 13 43
Resolution of nodule-related
symptoms 11 43
Patients with hyperfunctioning
nodules 12 20
ATD withdrawal/thyroid function
normalization 4 20
∗
Patients with cosmetic concerns 37 74
Excellent cosmetic results 35 65
Outcomes RFA(=37)
Surgery
(=74)
Tolerability
Patients without levothyroxine prior to
treatment 31 68
Hypothyroidism 0 17∗
Total number of procedures 38 74
Postoperative pain 2 74∗
Complication rate 2 10∗
∗
𝑃 < 0.05 versus RFA. ATD, antithyroid drugs; RFA, radiofrequency
ablation.
were only transient and resolved within 6 months. These
included 4 cases of transient hypocalcemia (serum calcium
< 8.5mg/dL with slightly reduced but normal PTH), 6 cases
of monolateral transient nerve palsy, and 2 cases of wound
complications. There were no cases of bleeding requiring
reintervention. Only 17 patents had to take levothyroxine
after surgery for the first time. Considering that 6 patients had
been taking levothyroxine before surgery, the majority (51) of
the remaining 68 patients, however, remained euthyroid.
Focusing on costs, the length of one RFA session was
45 minutes and it was performed in an outpatient regimen
and cost of C1,661.50. The mean operative time for hemithy-
roidectomies performed in a standard inpatient regimen was
80 minutes, the length of the hospital stay was 2.33 days, and
their mean cost was C4,556.30. In the group requiring short-
stay surgery, mean operative time was 82.5 minutes, hospital
stay was 1 day, and the cost was C4,139.40, as reported in
Table 3.
Having said that, another aspect we considered was the
contribution to patientmanagement of final pathology, which
only occurred in the surgical approach. Final pathology
showed that 68 patients out of 74 (92%) presented with
benign thyroid nodules. 44 noduleswere follicular adenomas,
12 were nodular thyroiditis, 6 were colloid lesions, 4 were
degenerative cysts, 1 was a Hurtle cell adenoma, and 1 was
a nodule within Riedel’s thyroiditis. So, despite the fact that
before surgery all FNAB were benign, 6 nodules (8%) were
found to be harbouring malignant cells on final pathology
and 5 cases were papillary microcarcinomas (<1 cm) while 1
case was a papillary carcinoma (>1 cm).
4. Discussion
Our comparative data show that RFA significantly reduces
thyroid nodule volume and relieves from nodule-related
clinical problems, such as local symptoms and cosmetic
concern, as effectively as surgery. In this study, 12 months
after RFA, thyroid nodules had shrunk by 70%, and the
best results were achieved in nodules with a mixed content
and an initial volume <35mL. This is in line with previous
studies demonstrating that RFA can reduce nodule volume
by 33–58% after one month, by 51–85% after six months
[11, 17], and by 93% after four years [18] from the procedure.
Different percentages of volume reduction can be attributed
to the number of sessions, which in our study were 1.03
per patient, whereas in other studies were 1.8 per patient
[18]. Moreover, although the length of our follow-up is 12
months, it has already been demonstrated that the volume
reduction achieved is maintained up to 4 years after RFA.
Volume reduction did not affect thyroid function in euthyroid
patients, which might have been due to the fact that there
was a negligible number of autoimmune thyroiditis [19], but
it was able to normalize TSH in some of the patients with hot
nodules. However, hyperthyroidism was completely resolved
only in 33% of patients, indicating that in our study RFA
was significantly less effective than surgery for the treatment
of hyperfunctioning nodules. This is consistent with what
has already been reported by the groups of Deandrea et al.
[11], who showed that hyperfunction was fully controlled in
24% of patients at 6 months after RFA, and by Faggiano
et al. [7], who further showed that hyperfunction was fully
controlled in 40% of patients with hot nodules at 12 months
after RFA. Having said that, Spiezia [10] and colleagues
have demonstrated that 2 years after RFA thyroid function
normalized in 100% of patients with pretoxic nodules and
in 53% of patients with toxic nodules. Further studies are
needed to clarify whether two RFA sessions could cure
hyperfunctioning nodules as effectively as surgery, since
incomplete recovery could be explained by the difficulty in
ablating the entire nodule and the regrowth of the untreated
peripheral portion [9]. So, our comparative study (RFAversus
surgery) shows that current recommendations onRFA [6] are
effective and applicable in treating thyroid nodules causing
symptoms and cosmetic concerns, while the best approach to
treat autonomously functioning nodules is surgery and not
RFA.
In general, consistent with what has been reported by
Lim et al. [18] RFA was safe and extremely well tolerated.
Postoperative pain was rare. Apart from two cases of mild
pain and one case of a transient voice change there were
no other complications, which could be ascribed to the
technique that was used. To avoid thermal nerve injury the
moving-shot technique and undertreating the area adjacent
to the nerve [13], also called the danger triangle, as shown
in Figure 2, have been suggested. In our study, one patient
developed a late-onset, painless thyroiditis with transient
thyrotoxicosis 3 months after RFA, which we report for
the first time as one of the potential RFA complications.
The presence of a thyrotoxicosis was suggested by thyroid
hormones’ increase and TSH decrease. The presence of
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Table 3: Costs of RFA and surgery.
RFA hEMItx Short-stay
Preprocedural costs
Radiological visit 25.30 Surgical visit 25.30 Surgical visit 25.30
Laboratory tests 100.20 Laboratory tests 291.10 Laboratory tests 291.10
US 41.70 ECG 14.40 ECG 14.40
Otolaryngological visit 1.70 Chest X-ray 26.90 Chest X-ray 26.90
Anaesthesiological visit 34.50 Otolaryngological visit 34.50 Otolaryngological visit 34.50
Anaesthesiological visit 34.50 Anaesthesiological visit 34.50
Procedural costs
(A) Equipment
Needle 1,240.70 Operating theatre 1,920.00 Operating theatre 1,980.00
US machine 3.00 Tools 197.60 Tools 197.60
Drugs 1.70 Drugs 664.00 Drugs 664.00
(B) Personnel
Radiologist 57.00 Surgeon (×2) 202.60 Surgeon (×2) 207.60
Nurse (×2) 45.50 Theatre nurse 41.50 Theatre nurse 42.50
Anaesthetist 57.00 Nurse (×2) 82.90 Nurse (×2) 85.00
Anaesthetist 101.30 Nurse (×2) 103.80
(C) Hospitalization
Hospital day — >24 hours hospital stay 862.50 <24 hours hospital stay 375.00
Follow-up costs
Laboratory tests 11.50 Laboratory tests 22.70 Laboratory tests 22.70
US 41.70 Otolaryngological visit 34.50 Otolaryngological visit 34.50
Total C1661.50 Total C4556.30 Total C4139.40
All costs are expressed in euro. ECG, electrocardiogram; hEMItx, hemithyroidectomy; RFA, radiofrequency ablation; US, ultrasonography.
a thyroiditis was suggested by the positivity of anti-TPO
antibodies, which were absent at baseline, and the suppressed
thyroid radioiodine uptake [20]. Such thyroiditis with thyro-
toxicosis was transient, as it resolved spontaneously within
a few weeks and it did not cause hypothyroidism. This case
of painless thyroiditis with thyrotoxicosis brings into mind
postaspiration thyrotoxicosis, which is believed to be an
inflammatory process that takes place after needle aspiration
of the thyroid and triggers the release of thyroid hormones
[21]. Given the proximity to RFA, it is conceivable that such
thyroiditis with thyrotoxicosismight have been caused by this
procedure through a mechanism similar to that of postaspi-
ration thyrotoxicosis [21]. As compared to RFA, surgery
caused hypothyroidism in 25% of patients and had a higher
complication rate, although they were all mostly mild and
transient, and nobody developed life-threatening problems
such as haemorrhage, laryngeal edema, or tetany, in keeping
with previous data [22, 23]. Overall, there were 6 cases of
transient nerve palsy, 4 cases of transient hypocalcemia,
and 2 cases of wound complications. Hypocalcemia after
hemithyroidectomy might be explained by the unintended
excision of one ormore parathyroids together withmetabolic
factors such as “hungry bones” associated with thyrotoxicosis
[22]. Although themajority of patients were very pleasedwith
surgical results, consistent with the literature [24], our data
on the baseline characteristics might suggest that patients are
not always comfortable with undergoing surgery. In fact, in
our view, only the onset of neck symptoms or strong cosmetic
concerns, which outweigh the lingering apprehension over
the risk of surgical complications, would have encouraged our
patients to undergo surgery.
The last decades have witnessed a quiet revolution in
relation to the management of benign thyroid diseases [25].
Advances in surgical techniques are making surgery not only
safer but also minimally invasive if not totally scarless. In
addition, thanks to the improvements in the management
of bleeding, pain, and hypoparathyroidism, hospital stays
have decreased to below 23 hours [26]. Today, the advan-
tages of outpatient surgery include reduced costs, reduced
inpatient waiting lists, increased availability of inpatient
beds, and the psychological benefit of avoiding prolonged
hospitalization. Having said that, there are clearly social and
clinical circumstances in which outpatient thyroidectomy
is not possible [15]. Moreover, even if it were feasible,
outpatient thyroid surgery remains controversial, given that
the likelihood of delayed haemorrhage and one case of death
have been reported [27]. Notwithstanding several potential
benefits, thosewho argue against outpatient surgerymaintain
that hospital cost savings should not be at the expense of
patient safety. In regard to this point, it is abundantly clear
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that RFA is safer. There is no risk of hypocalcemia, nerve
injury can be easily avoided (voice changes are reported
in 1% of cases), and there have been no reports so far
of life-threatening events [6, 13, 18, 19]. In addition, RFA
does not require general anaesthesia. So, RFA could prove
useful for treating weak or elderly patients or those with
challenging hemostasis, comorbidities, and other clinical
or social issues not conducive to surgery. In addition to
its efficacy and safety, here we show that RFA compares
extremely favorably to surgery in terms of costs, as it costs
roughly 2.6 times less than surgery, without including the
fact that sick-leave is significantly shorter and social costs are
significantly lower. However dramatically renewed surgery
might be, the greatest shift in the future routine management
of benign thyroid nodules will probably be determined by
the availability of nonsurgical,minimally invasive techniques.
These techniques together with recent advances in molecular
biology are likely to minimize unnecessary surgery [28].
Previous studies have reported that malignancy can be
found within a benign nodule. The group of Arora and
colleagues analysed 826 thyroid surgical specimens and
came upon 8 carcinomas (2%) within benign nodules [29].
In another work, Park and colleagues discovered occult
papillary carcinomas in 9.2% of adenomatous goiters and
4.3% of follicular adenomas [30]. This is in line with the
recent study carried out by Wang and collaborators who
showed that on average 6% of benign nodules are found
postoperatively malignant by cytopathology diagnosis [31].
These findings clearly demonstrate that some benign nodules
may harbour microscopic foci of malignancy that can be
missed at the FNAB due to sampling error. It is not clear
when these foci developed, whether they are bound to grow,
and whether molecular biology will enable us to overcome
this issue by differentiating these nodules from those that are
totally benign [32].Herewe found 6 carcinomas in 74 nodules
(8%) that had been classified as benign nodules by FNAB.
The majority of them (5 out of 6) were microcarcinomas. It
has to be noted, though, that before surgery FNAB had not
always been performed with ultrasonography. It is exactly
for reducing the likelihood of false cytologically benign
FNAB that before RFA it is recommended [6] to perform
two ultrasonographic-guided FNAB, in both functioning and
nonfunctioning nodules, as we did in this study before RFA.
It is absolutely clear that the strength of surgery is that it
allows for the final pathology and therefore the diagnosis and
cure of cancer.However, it is argued that low-risk thyroid can-
cer, such as microcarcinomas, is being overtreated nowadays
[33] as small papillary cancers may never progress to cause
symptoms or death. To back this view a recent observation
trial on papillary thyroid microcarcinoma has in fact shown
that tumor enlargement and new onset of node metastases
were detected in only 6.5% and 1.4% of patients after 5 years
of observation [34]. Moreover, none of the patients having
a microcarcinoma who underwent surgery after 5 years of
follow-up showed postoperative carcinoma recurrence and
none of the patients who underwent observation showed
distant metastasis or died of thyroid carcinoma. These data
would therefore suggest that papillary microcarcinoma has
an indolent nature and immediate surgery is not mandatory
[35]. Moreover, a recent study by the group of Valcavi has
demonstrated that percutaneous laser ablation is technically
feasible for complete destruction of papillary microcarcino-
mas [36]. Still, one of the biggest issues about the use of
RFA on thyroid nodules is that we still do not know its
impact on malignancy in the long term. Although RFA has
been successfully used for locoregional control of cancer or
improvement of cancer-related clinical symptoms in patients
with recurrent thyroid cancer and either a high surgical risk
or unwillingness to undergo repeated surgery, there are no
long-term follow-up data on radiofrequency ablated benign
thyroid nodules harbouring malignant cells and therefore on
how to monitor these cases. It is exactly for this reason that it
would be sensible to continue the monitoring of the ablated
nodules at least yearly for 5 years. Having said that, if RFA
could cure occult carcinomas, then it would definitely kill
three birds (efficacy, safety, and costs) with one stone.
5. Conclusion
In conclusion, our comparative study suggests that RFA
represents an effective alternative to surgery, which is very
expensive and occasionally unnecessary, for the treatment of
benign thyroid nodules causing local symptoms or cosmetic
concerns. Nevertheless, this study does not dismiss surgery,
which, on the contrary, ismore effective than oneRFA session
for treating nodules with an initial volume greater than 35mL
as well as for autonomously functioning nodules. Since RFA
does not allow for final pathology, patients should undergo
two ultrasonographic-guided FNAB prior to the procedure
and should be followed at least yearly for five years.
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